Czechoslovak Group Builds Chemicals Bridgehead and Fires Up Ukraine Munitions Line, Yet Shares Continue to Slide

Czech defense conglomerate CSG acquires 20.1% economic exposure to Alzchem for critical nitrocellulose, while launching NATO-standard artillery shell production in Ukraine to boost annual output to 850,000 rounds by 2026.

The Czechoslovak Group (CSG) is advancing on two industrial fronts simultaneously. Over the past week, the Czech defence conglomerate quietly amassed a 20.1% economic exposure to German specialty chemical firm Alzchem Group, while across the border in Ukraine a new artillery shell production line under licence came online. Both moves deepen CSG’s grip on the munitions supply chain, yet the stock continues to trade near its 52-week low.

The Alzchem stake is structured in two layers. A direct holding of 9.9% of voting rights sits with CSG subsidiary STALUNA TRADE a.s., while cash-settled total-return swaps — running until May 2027 — provide economic exposure to an additional 10.2% of voting rights. Those derivatives do not confer direct voting power, meaning CSG’s formal influence over Alzchem remains limited for now. Alzchem has stated that the transaction does not change its board composition or strategic direction, describing CSG as a long-term investor.

Alzchem is no niche player in the chemicals world. The company posted revenue of €562.1 million in 2025 and earnings before interest, tax, depreciation and amortisation of €116.5 million. It employs more than 1,700 people across four German sites and one Swedish plant, and its product range spans nutrition, pharmaceutical raw materials and high-performance materials with defence applications — notably nitrocellulose, a critical input for propellants.

CSG has previously flagged vertical integration as a margin driver. In its 2025 annual results — which showed group revenue of €6.7 billion, adjusted operating EBIT of €1.6 billion and an order book of €15 billion — the company explicitly referenced securing critical precursor materials. The Alzchem build-up fits that pattern, even though no formal supply contract or integration agreement has been confirmed.

On the production front, CSG reached a milestone on 1 June. A licensing partnership with Ukrainian Armor has begun manufacturing NATO-standard artillery shells inside Ukraine. The initial setup targets 100,000 rounds per year of 155 mm calibre and 50,000 rounds per year of 105 mm calibre. CSG provides the licence, technology support and high-value components from the Czech Republic for final assembly and testing. The arrangement is part of a broader strategy to decentralise manufacturing while keeping quality control tight.

The artillery ramp-up extends beyond Ukraine. CSG aims to push total heavy-calibre shell production to 850,000 units annually by the end of 2026. A new line for long-range ammunition in Slovakia, with a capacity of 70,000 rounds, is already running at full tilt. The company’s “Ammo+” and “CSG Defence” segments are leading the charge.

CSG’s first-quarter 2026 numbers underscore the operational momentum. Revenue rose 13.8% year-on-year to €1.54 billion, while the order book hit a record €17 billion. A further €27 billion worth of projects are in negotiation. Management maintained its full-year guidance: revenue between €7.4 billion and €7.6 billion, with an adjusted EBIT margin of 24% to 25%.

Yet the stock tells a different story. CSG shares changed hands at €16.25 on the back of the Alzchem disclosure, roughly 51% below the 52-week high of €33.81 set in January 2026. Over the preceding seven trading sessions, the stock lost more than 14%. The 52-week low of €15.73 is not far beneath the current level.

The disconnect between operational performance and market sentiment is familiar to CSG watchers. While the Ukrainian production line and the Alzchem stake both reinforce the group’s push up the value chain — beyond finished weapon systems into core materials and regional manufacturing — investors appear to be waiting for concrete proof of integration benefits. Whether the Alzchem position remains a pure financial bet or evolves into a visible industrial partnership will only become clear with future mandatory filings. For now, CSG has offered two tangible signals that it is actively securing its supply base, even as the share price continues to struggle.